Journal
CELL
Volume 180, Issue 3, Pages 490-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2019.12.030
Keywords
-
Categories
Funding
- National Institute of Health [U54HL119893, R01HL113032, R01HL134183, R01GM098672, S10OD020054, S10OD021741, P41CA196276, R01DK093646]
- National Institute of Health (UCSF Liver Center) [P30DK026743]
Ask authors/readers for more resources
Integrin alpha v beta 8 binds with exquisite specificity to latent transforming growth factor-beta (L-TGF-beta). This binding is essential for activating L-TGF-beta presented by a variety of cell types. Inhibiting alpha v beta 8-mediated TGF-beta activation blocks immunosuppressive regulatory T cell differentiation, which is a potential therapeutic strategy in cancer. Using cryo-electron microscopy, structure-guided mutagenesis, and cell-based assays, we reveal the binding interactions between the entire alpha v beta 8 ectodomain and its intact natural ligand, L-TGF-beta, as well as two different inhibitory antibody fragments to understand the structural underpinnings of alpha v beta 8 binding specificity and TGF-beta activation. Our studies reveal a mechanism of TGF-beta activation where mature TGF-beta signals within the confines of L-TGF-beta and the release and diffusion of TGF-beta are not required. The structural details of this mechanism provide a rational basis for therapeutic strategies to inhibit alpha v beta 8-mediated L-TGF-beta activation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available